On September 5, 2025, the National Administration of Medicines, Food, and Medical Technology (ANMAT) issued Provision No. 6559/2025, expanding the requirement of bioequivalence and/or bioavailability studies to oral pharmaceutical forms of hypoglycemic drugs.
This measure applies to medicinal products whose…
The case of dolutegravir in Colombia highlights the ongoing global debate about balancing public health priorities with intellectual property rights. Faced with the challenge of providing equitable access to a critical HIV treatment, the Colombian government took…
By Marco Antonio García Euroza. Senior Patent Consultant.
Extending patent because of the delays incurred
In October 2020, the highest Mexican Court, the Mexican Supreme Court, issued an unprecedented decision on extending patent No. 238942 because of the delays incurred…
